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delivery depends on efficient delivery of genetic material to target cells and achieving gene expression in long term [8] . Viral gene delivery vectors, for example adenoviruses, could induce long term expression due to its chromosomal integration ability. Yet viral vectors have several concerns regarding safety, like the danger of insertional mutagenesis. Unlike viral vectors, non-viral delivery methods are safer, non-toxic, cheap, with low immunogenicity and producible in large batches [9] .
Solid Lipid Nanoparticles (SLNs) are colloidal systems made of lipids that are solid in room temperature. They have similar ingredients with lipid nanoemulsions and liposomes. They all are lipid suspensions dispersed in water [10] . SLNs have lots of advantages compared to similar delivery systems: they don't show toxicity problems; they are biocompatible and producible in very small sizes (10-1000 nm); furthermore, they can be loaded with both hydrophobic and hydrophilic materials [11] . SLNs have proven record functioning as useful tools for nucleic acid delivery [12, 13] . Due to its compatibility with cationic lipids, nucleic acids can be attached to SLNs via electrostatic interactions.
Niosomes are carrier systems like liposomes, except that non-ionic surfactants replace phospholipids of liposomes. Biggest advantage of niosomes compared to liposomes is that they are very cheap to produce. Also, they have chemical stability. Niosomes generally have 3 components; non-ionic surfactant, helper lipid (usually cholesterol) and cationic lipids [14, 15] . While non-ionic surfactants generate micellar vesicles, helper lipids stabilize the structure. And cationic lipids are responsible for electrostatic interactions with negatively charged nucleic acids.
RESULTS AND DISCUSSION

Construction of ternary phase diagram
Titration for generating the ternary phase diagram was conducted in water jackets, shown in Figure 5 , at 80°C which is at least 10°C above the lipids melting point. After generating phase diagram, a point was selected in green area to produce SLNs. 
Gel retardation assay
Cationic SLN and Niosome formulations' complexation ability with pcDNA3.ING4 plasmid DNA were evaluated with gel retardation assay ( Figure 2 ). As can be seen from the gel images, both SLN and Niosome formulations were retarded gradually as the amount of formulation increases. After the lane 6 (DNA:SLN & DNA:Niosome : 1:1 (v/v)), both SLN and Niosome exhibited favorable DNA binding ability. Both of the formulations contain similar amount of cationic material and final dilutions are same as well. That could be the reason that they showed optimal complexation at the same value (1:1, v/v). 
Dynamic light scattering (DLS) measurements
DLS measurements were performed to investigate particle size and zeta potentials of formulations before and after the complexation with plasmid DNA. As can be seen from the results on Table 1 , all formulations are in nanometer range. Particle size of SLN formulation increased from 9.8 to 65.5 nm after the complexation with DNA which was expected due to several DNA and SLN molecules attaching each other. As in SLNs, vesicle size increased from 483.2 to 504 nm; zeta potential decreased from 64.5 to 59.9 mV in niosome formulation. Decrease in zeta potential values can be explained with the negative charge of pcDNA3-ING4 which was measured as -7.32 ± 5.35 mV. As a result, obtained net particle size and zeta potential values after the complexation procedure are sufficient for an efficient transfection [16] . 
Serum stability study
Serum stability study was conducted to investigate the DNA protection ability of formulations from serum nucleases. As can be seen in Figure 3A , naked DNA is degrading in the serum without any protection. Protection ability of SLNs and niosomes were observed in 24 hours periods at 3 different intervals of time (1, 6 and 24 h). If we compare lane 1 (control DNA) with the others, it can be seen that the SLN formulation has protection ability in 10% FBS at only hour 1 ( Figure 3B , lane 2). However, Niosome formulation has better serum protection than the SLNs. At any intervals of time and any FBS percentages that was tried, niosomes has full protection of DNA ( Figure 3B -C-D, lanes 4-5). It has previously been discussed that, protection of pDNA against enzymes is not related with complexation efficiency entirely. Protection ability of DNA carrier systems against nucleases is associated with various physicochemical properties including particle size, zeta potential, surface structure and shape. These characteristics are probably determining the amount of plasmid DNA on the surface and exposure of DNA to nucleases [17] . Therefore, high pDNA protection ability of niosomes against serum nucleases can be explain with their high zeta potential and vesicle size properties. 
XTT cell proliferation assay
Naked pDNAs and formulations were tested on MCF-7 cells for evaluation of their cytotoxic effects ( Figure 4 ). As can be seen in the Figure 4 on the left, no significant difference was found between pcDNA3 and pcDNA3-ING4 (p>0,05).
Unloaded niosome formulation and pcDNA3 loaded Niosomes have proliferative effect at 5 µl dose. This effect may be caused by the nutrition ability of cholesterol present in the formulations. Niosome formulation contains fair amount of cholesterol. Previous literatures reported that cholesterol has the ability of supporting cell growth in mammalian cells [18] . Among the pcDNA3.ING4 treatment groups of niosome formulation, 5 µl dose has the best effect as compared to other doses. Statistical analysis supports that finding (p<0,001). At 10 µl dose, viability remained between 70-90% with no statistically significant difference (p>0,05).
As unloaded SLNs and pcDNA3 loaded SLNs displayed low toxicity at 2 and 5 µl doses, they can be considered suitable for application at these doses. The antiproliferative effect of pcDNA3.ING4 loaded SLNs is statistically significant compared to pcDNA3 loaded SLNs at these dose (99% vs. 70% for 2 µl dose p<0,05, and 89% vs. 57% for 5 µl dose p<0,05).
In both Niosomes and SLNs, toxic effect was observed at higher amounts. It is a well-known fact that highly charged nanoparticles may cause cytotoxicity by disruption the cell membrane [19] . Cationic charge of our formulations decreased after complexation according to Table 1 . Unloaded niosomes and SLNs have higher toxicity than the pDNA loaded formulations at high doses according to Figure 4 which supports the aforementioned statement. 
Morphology of SLNs and niosomes
Morphologic structure of SLNs and niosome vesicles are observed with high contrast electron microscopy ( Figure 5 ). TEM images shoved that both SLNs and niosomes has spherical structure, and their sizes are in nanometer range which is supporting the DLS measurements (Table 1 ). Figure 5 . TEM images of SLNs (on the left) and niosomes (on the right).
Stability of SLNs and Niosomes
Particle size and zeta potential values of SLNs and Niosomes were measured at 1st, 30th, 45th and 60th days following the preparation of formulations. Results were given in Table 2 . As can be seen from the measurement results, particle sizes of SLNs are stable for a period of two months. There is a slight decrease in zeta potential with time. However, particle size and zeta potential values can be considered adequate for complexation with plasmid DNA within 45 days. As for the niosomes, they are unstable due to the increase in vesicle size. Vesicle size of the prepared niosomes increases dramatically with time. However, they retain their original vesicle size if the sonication step is repeated. As can be seen from the Table 2 , there is no significant change in their zeta potential values. Nevertheless, it can be said that SLNs are more suitable for long term storage due to their particle size stability. Table 2 . Particle size and zeta potential stability of SLNs and Niosomes (PS: particle size (nm), VS: vesicle size (nm), ZP: zeta potential (mV), SD: standard deviation).
Day
SLNs Niosomes 
PS ± SD ZP ± SD VS ± SD
CONCLUSION
In this study, we focused on development of novel SLN and niosome formulations for ING4 delivery. Both formulations developed in this study have appropriate size and zeta potential for plasmid DNA delivery. TEM images of SLNs and Niosomes shows that they have spherical shape and nanometer ranged sizes. Niosomes have better serum stability than the SLNs. Cell culture studies have shown that both formulations have cytotoxic effect at certain doses on MCF-7 cell line when they were complexed with pcDNA3.ING4 while they are non-toxic when complexation is performed with pcDNA3 control DNA. Naked DNAs has no significant effect on viability according to XTT cell proliferation assay. As a result, it can be concluded that the developed SLNs and Niosomes are candidate carrier systems for plasmid DNA delivery.
MATERIALS AND METHODS
Materials
pcDNA3-ING4 plasmid was purchased from Addgene as a bacterial stab (USA). pcDNA3 plasmid DNA was kindly given as a gift by Prof. Dr. Zeki Topçu (Ege University, Faculty of Pharmacy, Pharmaceutical Biotechnology Dept., Izmir, Turkey). Compritol HD5 ATO was a gift sample from Gattefose (France). DDAB was purchased from TCI (Japan). DMEM F12, FBS, and XTT cell proliferation kits were purchased from Biological Industries (USA). Esterquat-1 was purchased from Gerbu Biotechnik (Germany). Chloroform, SDS, Span 80 and Tween 80 were purchased from Sigma Aldrich (Germany). PBS tablets were purchased from Applichem (Germany). 
Preparation of Niosomes
Niosomes were prepared with thin film hydration method [21, 22] . Briefly, Span 80, cholesterol and DDAB were weighed accurately at molar ratio of 6:2:2 in a 50 mL round bottom flask. Mixture was dissolved in 10 mL chloroform. Organic solvent was slowly evaporated at 55°C under vacuum, using rotary evaporator (Heidolph 4000, Germany). Remnants of chloroform were removed with nitrogen. The dried film on the inner side of round bottom flask was hydrated with 10 mL PBS (pH:7.4). Final dispersion was sonicated for 3 mins in a bath sonicator to obtain small sized vesicles (Elmasonic E100, Germany). Niosome preparation is represented schematically in Figure 7 .
DLS Measurements
Dynamic Light Scattering measurements were performed with Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., UK). Scattering angle was 173° for particle size measurements. Zeta cuvettes were used for zeta potential measurements. Zeta potential was calculated by a software using Smoluchowski equation. Three measurements were conducted for each sample.
Complexation with Plasmid DNA
Complexation between cationic formulations and negative charged Plasmid DNA occurred via electrostatic interactions. Complexation efficiency of formulations were evaluated with gel retardation assay [23, 24] . Different volumes of formulations and DNA solution were mixed and vortexed at 25°C for 30 minutes.
Then complexes were applied to 1% agarose gel electrophoresis in Tris-acetate-EDTA buffer (100 V, 30 min). DNA bands were detected via EtBr staining. Agarose gel photographs were taken with UV transilluminator. DNA stock solution was 100 µg/ml.
Optimized complexation ratios for SLNs were 2.5:1 (SLN:DNA), and 1:1 (Niosome:DNA) for niosomes (v/v). 
In Vitro Serum Stability
Protection of complexed DNA against serum was evaluated with serum stability study at 37°C. 10% and 50% fetal bovine serum was used for 1, 6 and 24-hour intervals. At the end of the incubation times, 0,5 M EDTA with Proteinase K was used as a reaction inhibition solution. Then, integrity of DNA was evaluated with agarose gel electrophoresis.
XTT cell proliferation assay
MCF-7 human breast cancer cell line was used for evaluation of the efficiency of our delivery systems. Cells were cultured in DMEM F12 medium supplemented with 10% FBS and 100 U/mL penicillin/streptomycin. Cells were grown in humidified atmosphere with 5% CO2 at 37°C.
Cells were seeded on 96 well plates at a concentration of 10000 cells/well and incubated for 24 hours before transfection. Then, formulations were added in specified amounts. After incubation time, cells were washed with PBS and XTT reagent applied according to manufacturer's instructions. Non-treatment cells are considered 100% viable in calculations. All treatment groups were in triplicates.
TEM Imaging
Morphology of prepared SLNs and Niosomes was investigated with FEI Tecnai G2 high contrast transmission electron microscope (FEI Co., USA). 10 μL of samples were placed on carbon coated 200 mesh copper grids and allowed to dry overnight at 25°C. Imaging was carried out at 120 kV.
Stability of SLNs and Niosomes
Particle size and zeta potential stability of prepared SLNs and Niosomes were investigated with DLS measurements at several time intervals (Malvern Zetasizer Nano ZS, Malvern Instruments Ltd., UK). Formulations were stored in 4°C in this period.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 6.0. Cell culture results were analyzed with Student's t-test, and p<0,05 value was considered as statistically significant.
